Introduction
Neuroblastoma is characterized by diverse clinical behaviours ranging from complete regression of the disease to rapid tumor progression and death (see 1 for review). Patient age and stage of disease are important factors in determining outcome. Infants often experience complete regression of their disease while the majority of children over 1.5 years of age have metastatic disease at diagnosis and a poor prognosis despite intensive therapy. Identification of recurrent genomic abnormalities has allowed classification of neuroblastic tumors into distinct genetic subtypes that are predictive of clinical behaviour. Tumors that have a high propensity for spontaneous regression usually exhibit only whole chromosome gains and losses, whereas metastatic neuoblastoma is characterized by numerous recurrent structural chromosome abnormalities.
The most common structural chromosome abnormalities are associated with aggressive clinical behaviour and include loss of chromosome 1p and 11q, MYCN amplification (MNA), and unbalanced gain of the long arm of chromosome 17 (2) (3) (4) (5) (6) ). An inverse relationship exists between MNA and 11q loss, indicating that these abnormalities represent distinct genetic subtypes of advanced stage neuroblastoma (5, 7, 8) . These two major genetic subtypes are further defined by loss of 1p in the MNA subtype and loss of 3p in 11q-tumors (4, 6, 8) . Unbalanced gain of 17q material is the most common abnormality detected in advanced stage disease, occurring in 80 to 90% of advanced stage tumors irrespective of MNA or 11q loss status (2, 3, 5) .
The numerous genes and genetic pathways affected by amplification of the MYCN transcription factor are only just beginning to be identified (9) ; moreover, the genes targeted by the many other recurrent chromosomal imbalances, such as loss of 11q, are unknown. Global analysis of gene expression patterns using contemporary technologies holds great promise for identifying the molecular determinants of neuroblastoma pathogenesis. Indeed, serial analysis of gene expression (SAGE) studies of MNA neuroblastoma have revealed that MYCN enhances the expression of a number of genes involved with protein synthesis (10) , while other SAGE studies have revealed that the MEIS1 oncogene is over-expressed in 25% of neuroblastoma (11) . Detailed SAGE studies for the purpose of classifying neuroblastoma or for relating specific chromosomal imbalances in these tumor types to patterns of gene expression have not been carried out.
The first microarray-based gene expression profiling study of neuroblastoma was published by Khan et al., (12) , who demonstrated that different small round blue cell tumors, including neuroblastoma, rhabdomyosarcoma, non-Hodgkin lymphoma and Ewing tumors, could be distinguished on the basis of their patterns of gene expression. Subsequent microarray studies have facilitated class separation of differentiating neuroblastoma tumors from poorly differentiated tumors (13) , as well as high risk tumors from low risk tumors (14, 15) .
Recent expression microarray studies of breast cancer cells indicate that chromosomal imbalances have a significant impact on global gene expression patterns (16, 17) and support the view that aneuploidy plays a major role in carcinogenesis (18) . We have used high-density oligonucleotide array-based gene expression profiling to identify transcripts that are differentially expressed in the 11q-, MNA and hyperdiploid subtypes of neuroblastoma. In addition, the expression patterns of genes associated with benign neuroblastic tumors (ganglioneuroma) was compared with patterns from neuroblastoma. Our study represents the first oligonucleotide microarray-based gene expression profiling study of primary neuroblastic tumors and cell lines which have also been characterized by metaphase comparative genomic hybridization analysis. We report that the major genetic subtypes of advanced stage tumors can be differentiated on the basis of gene expression profiles and that distinct patterns of gene expression can be correlated with specific genomic alterations. A number of genes were identified which likely exhibit tumor stage-specific expression profiles. Finally, the implications of our studies with respect to understanding the molecular basis of neuroblastoma progression are discussed. Histology from each specimen was reviewed and tumors graded according to the International Neuroblastoma Pathology Classification (INPC) system (Table 1) (19, 20) . All tumors were obtained at diagnosis prior to chemotherapy. We were able to provide pathologic assessment of some of the GNB material by the use of tissue blocks mirroring the material used for RNA extraction in two of the GNB cases (No. 56 and 59). Examination of these tissue sections showed that the sampled material in Case 56 was devoid of Schwann cells, being composed of 100% neuroblastic tissue, while the sample from case 59 was composed of 80% neuroblastic tissue and 20% Schwann cells. Case 27 exhibited an almost completely uniform histological appearance, with the vast bulk of the tumor devoid of Schwann cells and composed of 100% neuroblastic tissue. It's designation as a GNB was based on the presence of a thin peripheral of ganglioneuromatous tissue not sampled in the material submitted for cytogenetics. Case 57 also exhibited a uniform histological picture, being composed of 90% Schwann cells and 10% neuroblastic cells.
Materials and Methods
CGH Analysis. Comparative genomic hybridization experiments were carried out as previously described (22) . CGH data on some cases has been published previously (6, 21) .
Oligonucleotide microarray Analysis. Affymetrix HU133A GeneChips (Santa Clara, CA) were used for all experiments. Following tissue homogenisation, total RNA was isolated via a Trizol-based extraction method (Life Technologies). The targets for Affymetrix microarray analysis were prepared as described by the manufacturer. Approximately 7.5 µg total RNA was used as starting material for the cDNA preparation. Single-and double-stranded cDNA synthesis was performed using the Superscript Choice System (Life Technologies) and an oligo-dT primer containing a T7 RNA polymerase promoter site (Genset). Biotin-labelled cRNA was prepared using the BioArray High Yield RNA Transcript labelling kit (Enzo). Approximately 15 µg cRNA was fragmented at 94° C for 35 minutes prior to hybridisation. The quality of labelled target was initially assessed using Genechip Test3 arrays. Hybridisation on the expression arrays was for 16hrs at 45 o C. Following hybridisation, standard washing and staining procedures were carried out on an Affymetrix Fluidics Station 640. Processed arrays were examined using a GeneChip Scanner 2500 and resultant image data managed via Affymetrix Microarray Suite software version 5.0 (MAS5.0). All of the raw data for each tumor is available at http://www.ebi.ac.uk/arrayexpress/ (accession number E-MEXP-83).
Statistical Analysis Methods. The overall data from all array experiments was scaled to a global intensity of 100 using MAS5.0 in order to control for within-array variation in intensity. The scaled data was then imported into GeneSpring software version 6 (Silicon Genetics, Redwood City, CA). Before applying clustering analysis, transcripts were normalised using GeneSpring by dividing the value for each transcript by the median of its measurements in all samples in order to account for the difference in detection efficiency between spots. A number of different filtering criteria were applied to the expression data to exclude transcripts that were not well-measured. For this purpose, those probe sets that displayed an absent call in all 24 samples (22 tumors and 2 cell lines) were removed, resulting in a 16,654 transcript list. The next filtering steps involved selecting transcripts which had a raw value of 100 in at least 3 samples, exhibited a 'Present' call in at least 3 samples, and whose corresponding transcripts varied in abundance by at least threefold from their median abundance in at least 2 samples. This combined filtering process yielded a more refined list of 2,660 differentially expressed transcripts. Both the 16,654 and 2,660 transcript lists were subjected to unsupervised two-way hierarchical cluster analysis, using the Pearson correlation as a similarity metric.
All subsequent analysis was performed using the Bioconductor and ADE4 packages of the open source statistical analysis software R. Recent spike-in and dilution studies have shown that the default expression measure provided by Affymetrix Microarray Suite software can be significantly improved using statistical models such as the Robust Multi-Chip Average (RMA) method (23) . Thus raw Affymetrix intensity measurements of all probe sets were converted into expression measurements using the RMA module. The C implementation of RMA in the Bioconductor package, Affy, was used, which normalises the corrected perfect match probes using quantile normalisation and calculates expression measures using median polish. These RMA expression measurements were also compared to MAS5.0 (Affymetrix, 2001) and Li and Wong DChip expression measurements (24) (data not shown). Average linkage hierarchical cluster analysis, using the Pearson correlation as a measure of similarity, of each of these datasets produced clusters of MNA and 11q-tumours, similar to that described in Figure 1 when the 16,654 gene subset was examined (data not shown).
Hierarchical cluster analysis partitions data into discrete hierarchical groups based on the trends within the data, but has the disadvantage that it sometimes forces arbitrary divisions of a dataset even when presented with continuous variation. Therefore, in addition to hierarchical cluster analysis, the data were analysed using correspondence analysis (COA, 25) . COA is an ordination technique that identifies the major trends in the data and distributes samples/genes along continuous axes in accordance with these trends. Since COA does not assume that the data falls into discrete clusters, clusters with continuous variation (gradients) can be distinguished from discrete groupings in the data. COA was performed using the ade4 package in R (27) , and similar patterns in the data were observed when results were compared to those obtained from hierarchical clustering analysis. In COA, the GN/GNB, MNA and 11q-tumours were observed on the first, second and third axes respectively, and thus represented the most significant features in the data (data not shown).
A number of methods were used to identify the genes that were most strongly associated with these groupings (GN/GNB, MNA and 11q-tumours). We used the supervised analysis method, between group analysis (BGA, 26), to rank the genes most associated with each of these clusters. BGA was performed using the ade4 module in R (27) and provided lists of genes most associated with each cluster. We used permutation-based modified t-tests to provide further confidence in these results. Differential gene expression was analyzed using a two-sample Welch t-statistic (unequal variances) with the step down resampling procedure, MaxT (28) , which provided permutation adjusted p-values that control for increased type I (false positive) error associated with multiple testing of large numbers of variables. These adjusted p-values were computed from 10,000 permutations using the multtest package in Bioconductor. However MaxT permutation adjusted p-values required lots of permutations, and we were limited by the subgroups size in the data. Thus differential gene expression associated with each group was tested using Significance Analysis of Microarrays (SAM, 29, 30) . SAM assigns a score to each gene based on the change in gene expression relative to the standard deviation within each cluster. The statistical significance of this score is determined by permutation of the samples and significance of the score is measured in terms of a false discovery rate (FDR). The lowest FDR at which a gene is called significant is the q value. In this study, SAM was performed on comparing each cluster to the remaining set (one class response, unpaired data, 1000 permutations) and q values are given in %.
TaqMan Quantitative Reverse Transcription (QRT)-PCR Analysis. We used the same total RNA pools for both oligonucleotide microarray and QRT-PCR analyses. Primers and TaqMan probes for respective target genes were designed using Primer Express software (Applied Biosystems). The sequences of the various PCR primer pairs and fluorogenic probes used are indicated in Table 2 . Single strand cDNA was synthesised from 1 µg total RNA using the ImProm-II RT System (Promega). Each reaction was performed in duplicate by using 50 ng cDNA as template. QRT-PCR was performed using the TaqMan Universal PCR Master Mix kit (Applied Biosystems), an ABI Prism 7700 (Perkin Elmer) instrument and the following thermal cycling conditions: 2 min at 55°C and 10 min at 95°C, followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 1 min and extension at 60°C for 1 min. For comparison of transcript levels between samples, a standard curve was determined using eight serial dilutions in duplicate of a mixed cDNA template obtained from the various neuroblastoma samples under examination. Values were then normalized relative to 18s rRNA concentrations, which were obtained from a standard curve generated via use of the TaqMan 18s rRNA Control Reagents kit (Applied Biosystems).
Immunohistochemical Detection of Topoisomerase-II-α. A tissue microarray (TMA) was constructed using formalin-fixed paraffin-embedded samples from 20 of the tumours that were used in the oligonucleotide microarray experiments. Two 0.6 µm cores from representative areas of each tumour were used in the TMA block. Tonsil tissue was used as a positive control. Sections (4 µm thick) were cut and de-waxed in xylene, rehydrated in alcohol and blocked for endogenous activity (3% H 2 O 2 and normal goat serum). Antigen retrieval was carried out by pressure-cooking in citrate buffer (pH 6.0). Sections were then incubated for 60 mins at room temperature with a monoclonal anti-topoisomerase II-alpha antibody (Novocastra Laboratories Ltd, Newcastle) at a dilution of 1:30. The sections were then washed with TBS (pH 7.6) to remove unbound antisera. Bound antibody was detected using the Envision detection system (DakoCytomation) with DAB as the chromogen.
The resulting immunostained sections were examined by a single pathologist (MMCD) in a blinded manner with a numerical counting grid using 20 and 40 X objective lenses and scored using previously published methods (31) . The topoisomerase labelling index (TLI) was calculated by dividing the number of positive cells by the total number of cells in the grid (average 591 cells per grid, range 60-1,200). As each tumour was represented in the array as two cores, there were two TLI scores derived for each tumour.
Results

Identification of Tumor Subtypes by Hierarchical Clustering.
A hierarchical clustering method was used to identify co-ordinately expressed transcripts and defined subgroups linked by similar patterns of gene expression (see Material and Methods). Cluster analysis of 16,654 transcripts resulted in a distinct separation of tumors with respect to stage and major genetic abnormalities (Fig1a). As illustrated in Figure 1b , a filtered collection of 2,660 differentially expressed transcripts also produced a hierarchical clustering result that was nearly identical to the result obtained using the much larger transcript set. The tumors were separated into two main branches. One branch contained the ganglioneuroma, some of the ganlioneuroblastoma (GN/GNB) tumors, and the majority of the low stage tumors (hyperdiploid and 11q-). Interestingly, two of the three 11q-tumors that were at low stage clustered with the low stage hyperdiploid tumors rather than with the high stage 11q-tumors irrespective of the fact that they had unbalanced gain of 17q. The second major branch consisted primarily of the advanced stage tumors. This branch was further subdivided into a sub-branch containing the MNA tumors and cell lines, and a sub-branch containing the high stage 11q-tumors and two low stage tumors, one that was hyperdiploid (case 54) and one that was 11q-(case 52). The MNA tumors clustered together irrespective of tumor stage; however, it is noted that this observation is based on a relatively small sample size. One of the cell lines clustering with the MNA primary tumors had MNA (Kelly/N206), while the other did not (SK-N-AS). The clustering of the SK-N-AS (not MNA) cell line with Kelly (MNA) and the MNA tumors may reflect alterations in gene expression that occurred in vitro and that probably promote growth in an in vitro environment. It should be noted that MYCN expression in Kelly was 109 fold higher than SK-N-AS, and that FISH analysis with a MYCN probe confirmed that SK-N-AS does not possess MNA (data not shown).
One tumor (case 25), originally classified as a stage 3 poorly differentiated neuroblastoma (NB), clustered close to the ganglioneuroma. Evaluation of the post-chemotherapy sample from case 25 showed a good deal of maturation, including ganglioneuromatous areas. It would be tempting to suggest that the expression profile of the primary tumor from case 25 may have had predictive value with regards to differentiation, even though the primary tumor was classified into an unfavorable INPC prognostic category. However, maturation following chemotherapy is a common phenomena in neuroblastoma so that the matter has clearly not been resolved by this single observation.
A subset of genes that contributed strongly to the classification of tumors depicted in Fig. 1 were identified from the 2,660 filtered transcript list using a number of statistical methods (see Methods section). Hierarchical clustering with these 31 genes (Fig. 2 ) produced a dendrogram that was very similar to that depicted in Fig 1, with only minor variation. The 31 gene list (Fig. 2) places all of the 11q-tumors in a separate cluster, irrespective of stage. The very tight clustering of the ganglioneuroma (case 57) with case 25 and case 56 is preserved, with all of the hyperdiploid low stage tumors branching from the GN/GNB cluster. The MNA tumors and cell lines form a distinct cluster that branches off from the GN/GNB/ low stage hyperdiploid tumor cluster, rather than from the 11q-cluster. Table 3 displays additional information on the expression profiles of the 12 genes that were most strongly differentially expressed in the 11q-tumors relative to all of the other tumors used in this study. P-values for each gene, determined by a t-test, and q values obtained by significance analysis of microarrays, are indicated in the table.
Exploratory data mining of gene expression profiles. Hierarchical clustering revealed a number of gene expression profiles that differed between the tumor groups, providing added insight into neuroblastoma progression. A number of gene expression clusters were evident within the data. The most striking feature of the gene expression patterns identified was the great variation observed between the GN/GNB tumors compared to the neuroblastoma tumours, which is evident in Cluster D (Fig. 1c) . Notably within this cluster, expression of the semaphorin 3B (SEMA3B) gene readily distinguished between differentiated and non-differentiated tumor types. Some of the genes within this cluster may represent a potential source of markers capable of distinguishing between aggressive and indolent neuroblastic tumors. Cluster C contained a number of genes that were highly expressed in the 11q-tumours. Increased expression of these genes may be contributing to the metastatic phenotype associated with tumours displaying loss of 11q. Genes displaying similar patterns of expression to the MYCN gene were found in Cluster A. Cluster B (Figure 3a) contained transcripts related to cell growth and proliferation, the majority of which were up regulated in the late stage metastatic tumors. Abnormal expression of these genes may be associated with increased cellular proliferation and survival in neuroblastoma.
Validation of oligonucleotide microarray studies by TaqMan QRT-PCR and immunochemistry. In order to confirm our oligonucleotide microarray-derived findings, we carried out TaqMan QRT-PCR analysis of six genes selected on the basis of exhibiting strong differential expression in different categories of neuroblastic tumors, such as low stage versus high stage. A subset of 14 of the 24 neuroblastoma samples was used for this purpose. The QRT-PCR results (Fig 3b-d) verified the patterns of gene expression revealed by oligonucleotide microarray analysis. In agreement with the oligonucleotide microarray data, high expression of BIRC5, TOP2A, CCNA2, and CDC2 was restricted to the neuroblastoma cell lines and five out of five late stage tumors, whereas, low expression of both genes was detected in one ganglioneuroma and all early stage tumors. High expression of SEMA3B was confirmed in one ganglioneuroma, while expression of this gene was almost undetectable in all neuroblastomas. In addition, expression of the MYCN gene was verified by QRT-PCR in this tumor subset.
To validate differential expression at the protein level, immunohistochemical staining was performed for TOP2A on a neuroblastoma tissue microarray (TMA) containing 19 of the tumor biopsies used for the oligonucleotide microarray analysis (Fig. 4) . Comparison of the gene expression data with the immunohistochemical staining results showed a strong correlation between TOP2A transcript levels and percent of cells that were immunoreactive for this antigen (Fig. 4) , with the exception of one discordant result for case 53. In this respect, oligonucleotide microarray analysis of case 53 indicated a moderate level of TOP2A mRNA expression, whereas immunochemistry indicated that all cells examined in the core section were negative for TOP2A. A conventional section from the paraffin block of case 53, however, exhibited strongly positive areas following immunochemistry indicating that we simply sampled a negative area (partially necrotic) when constructing the TMAs.
Validation of oligonucleotide microarray results by comparison of specific patterns of gene expression with published results. The expression patterns of genes determined by oligonucleotide microarray experimentation correlated well with expectations based on previously reported gene expression studies of neuroblastoma. For example, the mean MYCN expression in the MNA primary tumors was approximately 14 fold greater than that observed in the hyperdiploid and 11q-tumors and was absent in the (GN/GNB) tumor cluster. Two genes, NCYM and DDX1, that have been noted to sometimes co-amplify with MYCN, showed highly elevated expression in some of the MNA tumors (NCYM was highly elevated in all MNA primary tumors and in the Kelly/N206 cell line, while levels of DDX1 was increased in case 55). Expression of the cell adhesion molecule CD44 and the ephrin ligand EFNB2 were significantly down regulated in the MNA tumors, consistent with previous reports (32, 33) . The neurotrophin receptor NTRK1 was either absent or expressed at very low levels in the MNA tumors and expressed at significantly higher levels in the low stage hyperdiploid tumors, consistent with published expectations (34) . The 11q-tumors had a mean NTRK1 expression level that was intermediate between the low stage hyperdiploid tumors and the MNA tumors. As far as we are aware, NTRK1 expression in GN/GNB tumors has never been reported. Curiously, NTRK1 expression was either very low or absent in these differentiated tumors, comparable to levels of expression in the MNA tumors. Discussion In this study we have combined metaphase CGH and oligonucleotide microarray based gene expression profiling technologies to further identify how physical genomic changes alter gene expression in different types of neuroblastic tumors. In particular, 12 genes were identified that are strongly differentially expressed in 11q-neuroblastoma relative to other subtypes of neuroblastic tumors. Ten of these genes have increased levels of expression in 11q-tumors, while two are down regulated (Table 3) . A number of the up-regulated genes have been previously implicated in oncogenesis. These included the known tumour marker KRT19 (35) and the CDH4 gene which has recently been shown to be up-regulated in the pediatric solid tumour rhabdomyosarcoma (36) . In addition, the gene encoding aldehyde dehydrogenase 1 family member A2 (ALDH1A2), an enzyme that catalyzes the synthesis of retinoic acid (RA) from retinaldehyde, has been implicated in T-cell acute lymphoblastic leukemia (37) . A number of the genes showing enhanced expression in 11q-tumors, such as IL-7 and LY6H, may be indicative of an enhanced immune response and the presence of infiltrating lymphocytes in the tumor tissue. The expression patterns of the majority of the genes listed in Table 3 , however, never have been reported in neuroblastoma and their gene expression patterns may be contributing to the phenotype associated with loss of 11q material. None of these genes map to the chromosome 11q region, and examination of the expression patterns of all genes mapping to 11q did not identify a candidate tumor suppressor gene(s) that is targeted by loss of heterozygosity on this chromosome. The 11q tumor suppressor gene, however, might not have a large enough change in expression to be detectable by microarray analysis, particularly if the tumorigenic effect is a consequence of haploinsufficiency. Loss of expression of this tumor suppressor gene nevertheless could have a profound effect on the expression of other genes, which is perhaps evidenced by the fact that a number of genes located throughout the genome have expression profiles that are associated with loss of 11q. Additional experiments, designed to determine if loss of 11q material is causally related to the gene expression patterns that are unique to 11q-tumors would be of considerable interest.
Hierarchical cluster analysis permitted us to distinguish four major genetic subtypes of neuroblastic tumors, namely GN/GNB tumors, low stage tumors possessing either hyperdiploidy or loss of 11q, high stage tumors with 11q loss and tumors with MNA (irrespective of stage). Clustering did not permit us to differentiate between 11q-tumors with and without loss of 3p, and it was not possible to correlate any pattern of gene expression with loss of 3p. This indicates that loss of 11q may contribute to alterations in global gene expression in a more significant manner than does loss of chromosome 3p, bearing in mind that the number of 3p-tumors included in the present study was small. Although loss of 3p may not have a major impact on the expression of genes on many different chromosomes, it could still play a significant role in neuroblastoma progression or differentiation.
Hierarchical cluster analysis classified tumors based on overall similarity in their gene expression patterns, reflecting the relationships that exist between the tumors. Two lower stage tumors (stage 1 and stage 2) with loss of 11q and unbalanced gain of 17q (cases 26 and 27) clustered with the hyperdiploid low stage tumors as opposed to the higher stage 11q-tumors when the expanded set of differentially expressed transcripts was used. Both of these patients are alive and have had no relapse events for 3 and 4 years, in spite of the fact that they have genomic abnormalities indicative of a poor clinical outcome. It is intriguing to speculate that loss of 11q, and gain of 17q material are insufficient events to lead to a global gene expression profile indicative of stage 4 neuroblastoma. This leads us to suggest that additional events, perhaps epigenetic in nature, are required for tumor progression and metastasis.
Ramaswamy et al (38) recently published a seminal microarray study of gene expression in unmatched primary and metastatic adenocarcinomas from diverse tissue sources. These investigators identified a gene expression signature (based on 17 genes) that distinguished primary tumor from metastatic tumor. A subset of the primary tumors displayed gene expression profiles that were more similar to the profiles of the metastatic tumors than the other primary tumors, leading the authors to conclude that the metastatic potential is encoded within the bulk of the primary tumor. This challenges the notion that metastatic cells arise from rare cells within primary tumor (39) . Ramaswamy et al., (38) also applied their 17 gene expression signature to the analysis of medulloblastoma and found that this cohort of genes provided a high level of discrimination between primary and metastatic tumors. We performed hierarchical cluster analysis with these 17 genes on our panel of neuroblastoma tumors, but found that this set of genes provided no discrimination between low stage and high stage tumors, or between the different genetic subtypes using GeneSpring software and our parameters for data normalisation (data not shown). This result leads us to conclude that the metastatic expression signature provided by this set of genes may not be universally applicable to all types of tumors.
Two lower stage tumours, case 52 (11q-/stage 2) and case 54 (hyperdiploid/stage2) clustered with the higher stage 11q-tumors in our data set. Interestingly, these two tumours also displayed an increased expression of the cell cycle genes CCNA2 and CDC2 as well as BIRC5 (survivin) and TOP2A, which appear to be associated with a more advanced stage of disease. It seems that these low stage tumors have expression profiles that correlate stronger with the advanced stage tumors and may provide further support to the concept that metastatic potential can be encoded within the bulk of the primary tumor at an early stage.
Our oligonucleotide microarray studies also provide additional novel insight into the expression of many different genes in different neuroblastoma subtypes. For example, Perel et al., (40) have demonstrated by in situ hybridization and immunofluorescence studies that galanin (GAL), which encodes for a short peptide of 29 or 30 amino acids, is expressed at much higher levels in neuroblastoma than in ganglioneuroma. Our results indicate that GAL is expressed at significantly higher levels in only some of the genetic subtypes of neuroblastoma relative to ganglioneuroma. Most notably, MNA tumors and low stage hyperdiploid tumors exhibited significantly higher GAL expression than what was detected in the ganglioneuroma cluster. Interestingly, GAL clustered very closely to the MYCN gene. GAL expression in the 11q-neuroblastoma, however, was reduced to levels that are comparable to ganglioneuroma. Peral et al. (40) did not report on the status of 11q in their non-MNA amplified tumors, which is probably why this observation was not noted. Our result indicates that strong down regulation of GAL expression is not confined to ganglioneuroma and for this reason may not be an accurate indicator of tumor differentiation.
A number of genes were highly expressed in the GN/GNB tumors versus the malignant tumors in which a signal was almost undetectable. Some of these genes, such as semaphorin 3b (SEMA3B) may be crucial tumor suppressor genes in neuroblastoma and loss of expression may be contributing to tumorigenesis and metastatic potential. SEMA3B plays a role in axonal guidance in neurons of the sympathetic nervous system and has recently been shown to play a role in the suppression of tumorigenicity in certain lung and ovarian cancer cell lines (41, 42) . SEMA3B was highly expressed in GN/GNB tumors, and was either not expressed or only very weakly expressed in all of the malignant tumors irrespective of stage or genetic abnormality. Although SEMA3B maps to the 3p21 region that is frequently deleted in neuroblastoma (particularly in the 11q-subtype), its expression could not be correlated with 3p deletion, due to the very weak expression. Nevertheless, the association of SEMA3B expression with differentiation of neuroblastic tumors, and its absence in poorly differentiated neuroblastoma suggests that this gene could potentially be a good marker for assessing whether NB may differentiate. A number of other potentially interesting genes were contained within this cluster including S100B and NDRG2. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and are involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. A previous study, which measured S100B by immunoassay, reported lower levels of the protein in patients with undifferentiated neuroblastomas (43) . NDRG2 is a member of the MYCN down regulated gene family and has recently been implicated in cell differentiation (44) . Absence of these genes in poorly differentiated neuroblastoma suggests that they could potentially be good markers for assessing whether NB may differentiate. Taken together these results suggest a possible role for SEMA3B, S100B and NDRG2 in the differentiation of neuroblastic tumours. However, analysis of additional tumors will be required to verify these results.
Examination of the differentially expressed gene clusters identified a number of genes that appeared to have a stage related pattern of expression. These included a number of cell cycle related genes including CCNA2 and CDC2, among others. The products of both of these genes were increased significantly in high stage tumors. Other genes displaying increased levels of expression in the high stage versus low stage tumors as determined by oligonucleotide microarray analysis included BIRC5 and TOP2A. These genes map to 17q25 and 17q21-22 respectively, which falls into a region consistently gained in high stage neuroblastoma. Increased expression of BIRC5 in advanced stage neuroblastoma has been reported previously (45) . Our results imply that increased TOP2A expression may also be part of the phenotype for malignant neuroblastoma cells. The gene encoding this enzyme functions as the target for several anticancer agents. A recent study reported that etoposide, a TOP2A inhibitor, induced apoptotic alterations in a neuroblastoma cell line (46) . Our results suggest that therapeutic options for neuroblastoma could therefore include appropriate topoisomerase II alpha-targeted drugs.
The classification of human cancers into prognostically significant groups is extremely important for optimal patient management. Although we have only discussed a fraction of the genes that varied in expression between the different genetic subtypes of neuroblastoma, the gene expression signatures discovered by our oligonucleotide microarray approach identified a number of potentially important genes. The proteins encoding these genes may represent new targets for improving neuroblastoma diagnosis and treatment. A more detailed analysis of individual genes may allow a more complete understanding of this disease. Many of the genes mentioned here clearly deserve high priority in future studies of neuroblastoma. Computed with maxT algorithm using multtest in R as described in (28) 2
Figure Legends
Reported q values (%) computed with SAM. The q value is the lowest false discovery rates (FDR) at which a gene is called significant. In general a q value <5 is considered significant. 3 Between group analysis using COA with the class groups defined. A + symbol indicates that the gene mean expression level in the 11q-tumors separated these tumors from the non 11q-tumors. ♦ Though these genes were ranked among the most significant genes in both SAM and between group analysis (BGA) of data, these genes were not among genes with statistically significant adjusted P values using the maxT algorithm. ns = not significant ↑ designates increased expression in the 11q-tumors relative to the other tumor groups. ↓ designates decreased expression in the 11q-tumors relative to the other tumor groups.
